MeSH D005185 - fallopian tube neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Amgen | Bevacizumab | Mvasi |  | 2017-09-14 |  |  |
| Amneal Pharmaceuticals | Bevacizumab | Alymsys |  | 2022-04-13 |  |  |
| Celltrion | Bevacizumab | Vegzelma |  | 2022-09-27 |  |  |
| Centus Biotherapeutics | Bevacizumab | Equidacent |  | 2020-09-24 |  |  |
| Genentech | Bevacizumab | Avastin |  | 2004-02-26 |  |  |
| GSK | Niraparib | Zejula | 2027-08-12 | 2017-03-27 |  |  |
| Immunogen | Mirvetuximab soravtansine | Elahere |  | 2022-11-14 |  |  |
| Johnson & Johnson | Niraparib, Abiraterone | Akeega | 2027-08-12 | 2023-08-11 |  |  |
| mAbxience Research | Bevacizumab | Alymsys |  | 2021-03-26 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
77%95/123
Phase 2
20%30/150
Phase 3
13%6/45
Approved: 4Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use